title: Reply to Fišer et al.: Myeloid reprogramming of Ph+ B-ALL: A potential therapeutic strategy.
authors.affiliation: Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305 rmajeti@stanford.edu.
authors.forename: Ravindra
authors.initials: R
authors.lastname: Majeti
authors.affiliation: Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305.
authors.forename: Christopher
authors.initials: C
authors.lastname: Dove
authors.affiliation: Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305.
authors.forename: James Scott
authors.initials: JS
authors.lastname: McClellan
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000378:metabolism*; D005260:Female; D006801:Humans; D008264:Macrophages / Q000166:cytology*; D008297:Male; D010677:Philadelphia Chromosome; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000378:metabolism*